488 related articles for article (PubMed ID: 34583746)
21. Drug-Coated Balloon vs Standard Percutaneous Transluminal Angioplasty for the Treatment of Atherosclerotic Lesions in the Superficial Femoral and Proximal Popliteal Arteries: One-Year Results of the MDT-2113 SFA Japan Randomized Trial.
Iida O; Soga Y; Urasawa K; Saito S; Jaff MR; Wang H; Ookubo H; Yokoi H;
J Endovasc Ther; 2018 Feb; 25(1):109-117. PubMed ID: 29264999
[TBL] [Abstract][Full Text] [Related]
22. 1-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease: Evidence From the SFA-Long Study.
Micari A; Vadalà G; Castriota F; Liso A; Grattoni C; Russo P; Marchese A; Pantaleo P; Roscitano G; Cesana BM; Cremonesi A
JACC Cardiovasc Interv; 2016 May; 9(9):950-6. PubMed ID: 27151609
[TBL] [Abstract][Full Text] [Related]
23. Treating Post-Angioplasty Dissection in the Femoropopliteal Arteries Using the Tack Endovascular System: 12-Month Results From the TOBA II Study.
Gray WA; Cardenas JA; Brodmann M; Werner M; Bernardo NI; George JC; Lansky A
JACC Cardiovasc Interv; 2019 Dec; 12(23):2375-2384. PubMed ID: 31806218
[TBL] [Abstract][Full Text] [Related]
24. Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial.
Jaff MR; Rosenfield K; Scheinert D; Rocha-Singh K; Benenati J; Nehler M; White CJ
Am Heart J; 2015 Apr; 169(4):479-85. PubMed ID: 25819854
[TBL] [Abstract][Full Text] [Related]
25. Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease: Twelve-Month Outcomes From the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies.
Krishnan P; Faries P; Niazi K; Jain A; Sachar R; Bachinsky WB; Cardenas J; Werner M; Brodmann M; Mustapha JA; Mena-Hurtado C; Jaff MR; Holden AH; Lyden SP
Circulation; 2017 Sep; 136(12):1102-1113. PubMed ID: 28729250
[TBL] [Abstract][Full Text] [Related]
26. One-Year Clinical Outcomes of the Legflow Drug-Coated Balloon for the Treatment of Femoropopliteal Occlusions Registry.
Stabile E; Gerardi D; Magliulo F; Zhelev D; Chervenkoff V; Taeymans K; Kotasov D; Goverde P; Giugliano G; Trimarco B; Esposito G
J Endovasc Ther; 2019 Feb; 26(1):26-30. PubMed ID: 30760132
[TBL] [Abstract][Full Text] [Related]
27. Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease.
Rosenfield K; Jaff MR; White CJ; Rocha-Singh K; Mena-Hurtado C; Metzger DC; Brodmann M; Pilger E; Zeller T; Krishnan P; Gammon R; Müller-Hülsbeck S; Nehler MR; Benenati JF; Scheinert D;
N Engl J Med; 2015 Jul; 373(2):145-53. PubMed ID: 26106946
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of a novel paclitaxel-nano-coated balloon for femoropopliteal angioplasty: one-year results of the EffPac trial.
Teichgräber U; Lehmann T; Aschenbach R; Scheinert D; Zeller T; Brechtel K; Blessing E; Lichtenberg M; Sixt S; Brucks S; Beschorner U; Klumb CT; Thieme M;
EuroIntervention; 2020 Apr; 15(18):e1633-e1640. PubMed ID: 31687933
[TBL] [Abstract][Full Text] [Related]
29. Network meta-analysis of drug-coated balloon angioplasty versus primary nitinol stenting for femoropopliteal atherosclerotic disease.
Abdoli S; Mert M; Lee WM; Ochoa CJ; Katz SG
J Vasc Surg; 2021 May; 73(5):1802-1810.e4. PubMed ID: 33249205
[TBL] [Abstract][Full Text] [Related]
30. Drug-Coated Balloon Angioplasty for Femoropopliteal In-Stent Restenosis.
Cassese S; Wolf F; Ingwersen M; Kinstner CM; Fusaro M; Ndrepepa G; Ibrahim T; Ott I; Lammer J; Krankenberg H; Fusaro M
Circ Cardiovasc Interv; 2018 Dec; 11(12):e007055. PubMed ID: 30562083
[TBL] [Abstract][Full Text] [Related]
31. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
Scheinert D; Schmidt A; Zeller T; Müller-Hülsbeck S; Sixt S; Schröder H; Weiss N; Ketelsen D; Ricke J; Steiner S; Rosenfield K
J Endovasc Ther; 2016 Jun; 23(3):409-16. PubMed ID: 27117972
[TBL] [Abstract][Full Text] [Related]
32. Matched comparison of uncoated and paclitaxel-coated balloon angioplasty for isolated popliteal lesions excluding bail-out stenting.
Böhme T; Noory E; Beschorner U; Bollenbacher R; Nührenberg T; Rastan A; Westermann D; Zeller T
Cardiovasc Revasc Med; 2024 Jun; 63():54-58. PubMed ID: 38245433
[TBL] [Abstract][Full Text] [Related]
33. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs.
Kayssi A; Al-Atassi T; Oreopoulos G; Roche-Nagle G; Tan KT; Rajan DK
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD011319. PubMed ID: 27490003
[TBL] [Abstract][Full Text] [Related]
34. Provisional Stenting Using the Zilver PTX Drug-Eluting Stent After Drug-Coated Balloon Angioplasty: Initial Experience From the Double Drug Dose "3D" Study.
Fanelli F; Cannavale A; Citone M; Santoni M; Gazzetti M; Falcone GM; Miele V
J Endovasc Ther; 2020 Feb; 27(1):34-41. PubMed ID: 31637956
[No Abstract] [Full Text] [Related]
35. Five-Year Safety and Effectiveness of Paclitaxel Drug-Coated Balloons Alone or With Provisional Bare Metal Stenting for Real-World Femoropopliteal Lesions: IN.PACT Global Study Subgroup Analysis.
Ansel GM; Brodmann M; Rocha-Singh KJ; Menk JS; Zeller T;
Circ Cardiovasc Interv; 2024 Feb; 17(2):e013084. PubMed ID: 38348677
[TBL] [Abstract][Full Text] [Related]
36. Drug-coated balloon versus plain old balloon angioplasty in femoropopliteal disease: An updated meta-analysis of randomized controlled trials.
Anantha-Narayanan M; Shah SM; Jelani QU; Garcia S; Ionescu C; Regan C; Mena-Hurtado C
Catheter Cardiovasc Interv; 2019 Jul; 94(1):139-148. PubMed ID: 30838719
[TBL] [Abstract][Full Text] [Related]
37. Methodology of the BIOPACT RCT, a Multi-center, Randomized, Non-inferiority Trial Evaluating Safety and Efficacy of Passeo-18 Lux Drug-Coated Balloon (DCB) of Biotronik Compared to the Medtronic IN.PACT Admiral DCB in the Treatment of Subjects with Lesions of the Femoropopliteal Artery.
Deloose K; Lansink W; Brodmann M; Werner M; Keirse K; Gouëffic Y; Verbist J; Maene L; Hendriks J; Brunet J; Ducasse E; Levent K; Sauguet A; Déglise S; Vandael F
Cardiovasc Intervent Radiol; 2022 Dec; 45(12):1855-1859. PubMed ID: 36058996
[TBL] [Abstract][Full Text] [Related]
38. Microcrystalline paclitaxel-coated balloon for revascularization of femoropopliteal artery disease: Three-year outcomes of the randomized BIOPAC trial.
Nowakowski P; Uchto W; Hrycek E; Kachel M; Ludyga T; Polczyk F; Żurakowski A; Kaźmierczak P; Granada JF; Nowakowska I; Kiesz RS; Milewski KP; Buszman PE; Buszman PP
Vasc Med; 2021 Aug; 26(4):401-408. PubMed ID: 33686879
[TBL] [Abstract][Full Text] [Related]
39. Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention.
Krishnan P; Farhan S; Schneider P; Kamran H; Iida O; Brodmann M; Micari A; Sachar R; Urasawa K; Scheinert D; Ando K; Tarricone A; Doros G; Tepe G; Yokoi H; Laird J; Zeller T
J Am Coll Cardiol; 2022 Sep; 80(13):1241-1250. PubMed ID: 36137674
[TBL] [Abstract][Full Text] [Related]
40. Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial.
Scheinert D; Schulte KL; Zeller T; Lammer J; Tepe G
J Endovasc Ther; 2015 Feb; 22(1):14-21. PubMed ID: 25775674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
